Nippon Shinyaku Co., Ltd., an enterprise established in Kyoto, Japan, in 1911, engages globally in the production and distribution of pharmaceutical products and functional foods. Its reach extends across Japan, Switzerland, and various international markets, with operations structured into two core divisions: Pharmaceuticals and Functional Food. The Pharmaceutical division concentrates on a wide array of therapeutic areas, encompassing conditions affecting the urinary system, inflammatory and allergic responses, hematologic malignancies, cardiovascular and metabolic disorders, gastrointestinal issues, and other diverse diseases. Its extensive product catalog features notable treatments such as Zalutia, designed for urinary difficulties arising from benign prostatic hypertrophy; Eviprostat, also for prostatic hypertrophy; Bladderon for frequent urination; and Estracyt, targeting prostate cancer. For erectile dysfunction, it provides Cialis. In hematology and oncology, the company's portfolio includes Vidaza for myelodysplastic syndrome; Cylocide and CylocideN for solid tumors, acute leukemia, and malignant lymphoma; Gazyva, a humanized anti-CD20 monoclonal antibody; Defiterio for sinusoidal obstruction syndrome; and Trisenox and Amnolake for relapsed and refractory acute promyelocytic leukemia. Nippon Shinyaku also offers Uptravi, Adcirca, and Opsumit for the management of pulmonary arterial hypertension, alongside VILTEPSO for muscular dystrophy. Other specialized medications include Lunabel LD and Lunabel ULD for dysmenorrhea; Erizas, a dry powder inhaler for allergic rhinitis; Azunol Gargle liquid, an azulene-based gargling solution; Isobide for oral osmotic diuresis and Meniere's disease; Cephadol for vertigo; Livostin for allergic rhinitis and conjunctivitis; Regtect, aimed at maintaining alcohol abstinence; and Onetram and Tramal for the treatment of cancer and chronic pain. Furthermore, the company actively conducts research, development, and marketing efforts in the fields of gynecology, otorhinolaryngology, and orthopedics. The Functional Food segment broadens the company's offerings, supplying various health-focused ingredients, food preservatives, protein preparations, dietary supplements, and a selection of spices and condiments.
The current price of NPPNY is $5.20 USD — it has decreased by -0.37% in the past 24 hours. Watch Nippon Shinyaku. stock price performance more closely on the chart.
What is Nippon Shinyaku. stock ticker?▼
Depending on the exchange, the stock ticker may vary. For instance, on OTC Link exchange Nippon Shinyaku. stocks are traded under the ticker NPPNY.
Is Nippon Shinyaku. stock price growing?▼
NPPNY stock has fallen by -4.15% compared to the previous week, the month change is a -3.44% fall, over the last year Nippon Shinyaku. has showed a +3.43% increase.
What is Nippon Shinyaku. market cap?▼
Today Nippon Shinyaku. has the market capitalization of 365.31M
When is the next Nippon Shinyaku. earnings date?▼
Nippon Shinyaku. is going to release the next earnings report on November 13, 2026.
What were Nippon Shinyaku. earnings last quarter?▼
NPPNY earnings for the last quarter are 0.92 USD per share, whereas the estimation was 0.61 USD resulting in a +51.72% surprise. The estimated earnings for the next quarter are N/A USD per share.
What is Nippon Shinyaku. revenue for the last year?▼
Nippon Shinyaku. revenue for the last year amounts to 1.12B USD.
What is Nippon Shinyaku. net income for the last year?▼
NPPNY net income for the last year is 196.4M USD.
Does Nippon Shinyaku. pay dividends?▼
Yes, NPPNY dividends are paid semi-annual. The last dividend per share was 0.1 . As of today, Dividend Yield (FWD)% is 3.74%.
How many employees does Nippon Shinyaku. have?▼
As of November 9, 2026, the company has 2,309 employees.
In which sector is Nippon Shinyaku. located?▼
Nippon Shinyaku. operates in the Health & Wellness sector.
When did Nippon Shinyaku. complete a stock split?▼
Nippon Shinyaku. has not had any recent stock splits.
Where is Nippon Shinyaku. headquartered?▼
Nippon Shinyaku. is headquartered in Kyoto, Japan.